In the fall of 2013, the National Cancer Institute re-launched the Innovative Molecular Analysis Technologies (IMAT) program, committing up to $10.5 million through unique funding mechanisms (3 year R21s and R33s) to better support investigators through both the early and advanced stages of technology development over traditional funding mechanisms for exploratory research. The IMAT program has supported the development of various analytical and sample processing platforms that have made substantial contributions across the cancer research continuum, and the process of winning an award remains highly competitive. A variety of IMAT-supported research projects will be highlighted to demonstrate the variety and high level of innovation evident in the IMAT portfolio of supported research. An emphasis will be placed on recently completed projects so that investigators interested in next generation tools may become aware of possible developments through NCI-funded projects for their research. In addition, trends from recently awarded projects will be described to provide insight for potential applicants on the nature of the program and the competition. Potential projects of interest and identified technology gaps will also be discussed. The IMAT program continues to represent a unique resource for highly innovative technology development.

Citation Format: Anthony Dickherber. Funding innovative technologies for cancer research at the National Cancer Institute. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3499. doi:10.1158/1538-7445.AM2014-3499